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Since the 1980s there has been a marked increase in the recognition and reporting
of highly invasive group A streptococcal infections with or without necrotizing fasciitis
associated with shock and organ failure. Such dramatic cases have been defined as
streptococcal toxic-shock syndrome. Strains of group A streptococci isolated from
patients with invasive disease have been predominantly M types 1 and 3 that produce
pyrogenic exotoxin A or B or both. In this paper, the clinical and demographic features
of streptococcal bacteremia, myositis, and necrotizing fasciitis are presented and
compared to those of streptococcal toxic-shock syndrome. Current concepts in the
pathogenesis of invasive streptococcal infection are also presented, with emphasis on
the interaction between group A Streptococcus virulence factors and host defense
mechanisms. Finally, new concepts in the treatment of streptococcal toxic-shock
syndrome are discussed.
An emerging pathogen can be one that is totally
new (e.g., human immunodeficiency virus), one that
was known but has only recently been identified
(e.g., Helicobacter pylori), or one that is old but has
learned new tricks. The last type is, as Dr. Stanley
Falkow contends, merely trying to “make a living”
in a changing environment. Regardless of environ-
mental pressures, many old pathogens have become
major clinical problems because of increased viru-
lence or antibiotic resistance (e.g., penicillin-
resistant pneumococcus, multidrug resistant Myco-
bacterium tuberculosis, methicillin-resistant
Staphylococcus aureus, and vancomycin-resistant
Enterococcus faecium).
Arguably, group A Streptococcus (GAS) is the
quintessence of an old organism that has become
more virulent. In this manuscript, the epidemiology,
clinical spectrum, and pathogenesis of GAS infec-
tion are discussed in relation to the streptococcal
toxic-shock syndrome (TSS).
Current and Historical Perspectives on the
Prevalence and Severity of Streptococcal Infections
The British tabloids have recently coined the
term “flesh-eating bacteria” to describe invasive ne-
crotizing infections caused by GAS and have sug-
gested that epidemics of streptococcal infection are
imminent. Such aggrandizement is unfounded, yet
it has served to heighten public awareness of this
sporadic, but serious, infectious disease. Strictly
speaking, an epidemic is defined as an increase in
the prevalence of disease over a baseline endemic
rate. In this context, we are, in fact, experiencing an
epidemic of severe invasive GAS infections; how-
ever, few concrete prospective population-based
data support this notion. Estimates suggest that the
incidence of these infections is 10 to 20 cases/
100,000 population. Thus, the stimulus for such
public interest has not been the incidence of the
syndrome, but more likely, the dramatic nature of
these infections.
Whether these types of group A streptococcal
infections will decline, stay the same, or increase is
not known. History is replete with descriptions of
epidemics of GAS infections and their nonsuppura-
tive sequelae. In the 1600s, epidemics of scarlet
fever spread from Italy and Spain to Northern
Europe (1), and in 1736, an outbreak occurred in the
American colonies, killing 4,000 people (2). Major
epidemics of rheumatic fever occurred in World War
II in the U.S. military (3). Soon afterward post-strep-
tococcal glomerulonephritis struck several regions
of the United States (4,5).
Many of these epidemics waxed and waned before
the advent of antibiotics, suggesting that either
changes in socioeconomic conditions or variations in
the expression of virulence factors by the pathogen
were responsible. This concept is best exemplified
by the extraordinary mortality rate of scarlet fever
documented in the latter part of the 1880s in New
York, Chicago, and Norway; 25% to 30% of children
with scarlet fever died during that period (5,6). By
1900, the mortality rate had dropped to under 2% in
all three locations. Since socioeconomic conditions
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antibiotics were not yet available, the decrease in
mortality rates must have been caused by reduced
expression of a streptococcal virulence factor or by
the slow acquisition of herd immunity to that factor.
The epidemiology of GAS infection is complex.
More than 80 different M types of S. pyogenes exist,
and five separate and distinct scarlatina toxins,
streptococcal pyrogenic exotoxins (SPEs) (5) have
also been described; some of these can be transmit-
ted to different M types by bacteriophage. Minor
drifts in the antigenic or virulence properties of GAS
could account for the 5- to 6-year cycles of scarlet
fever documented by Kohler (9). In the same way as
antigenic shifts in influenza virus cause pandemics,
major alterations in GAS virulence properties could
cause major changes in clinical disease. The recent
increases in severe GAS infections, following a 50-
to 60-year span of relatively benign clinical disease,
support this notion.
Acute Life-Threatening Group A Streptococcal
Infections
Streptococcal TSS
Recently, severe invasive GAS infections associ-
ated with shock and organ failure have been re-
ported with increasing frequency, predominantly
from North America and Europe (8-18). These infec-
tions have been termed streptococcal toxic-shock
syndrome (TSS; Table 1) (19). Persons of all ages are
affected; most do not have predisposing underlying
diseases (11,20-25). This is in sharp contrast to
previous reports of GAS bacteremia, in which pa-
tients were either under 10 or over 60 years of age,
and most had underlying conditions such as cancer,
renal failure, leukemia, or severe burns or were
receiving corticosteroids or other immunosuppress-
ing drugs (20-22). The complications of current GAS
infections are severe; bacteremia associated with
aggressive soft tissue infection, shock, adult respi-
ratory distress syndrome and renal failure are com-
mon; 30% to 70% of patients die in spite of aggressive
modern treatments (Table 2) (1,8,24-26).
Acquisition of Group A Streptococcus
The portal of entry of streptococci cannot be
proven in at least half the cases (8) and can only be
presumed in many others. Patients with sympto-
matic pharyngitis rarely develop streptococcal TSS,
though such cases have been reported, especially in
the last year. Procedures such as suction lipectomy,
hysterectomy, vaginal delivery, bunionectomy and
bone pinning have provided a portal of entry in many
cases (author’s unpublished observations). Most
commonly, infection begins at a site of minor local
trauma, which frequently does not result in a break
in the skin (8). Numerous cases have developed
within 24 to 72 hours of minor nonpenetrating
trauma, resulting in hematoma, deep bruise to the
calf, or even muscle strain. Virus infections, such as
varicella and influenza, have provided a portal in
other cases. In some cases the use of nonsteroidal
antiinflammatory agents may have either masked
the early symptoms or predisposed the patient to
more severe streptococcal infection and shock (1).
For the most part, these infections have occurred
sporadically and have not been associated with clus-
ters of cases or minor epidemics, though outbreaks
of severe GAS infections have occurred in closed
environments such as nursing homes (27,28).
Clinical Symptoms
Pain—the most common initial symptom of strep-
tococcal TSS—is abrupt in onset and severe, and
usually precedes tenderness or physical findings.
The pain usually involves an extremity but may also
mimic peritonitis, pelvic inflammatory disease,
pneumonia, acute myocardial infarction, or peri-
carditis. Twenty percent of patients have an
influenza-like syndrome characterized by fever,
chills, myalgia, nausea, vomiting, and diarrhea (8).
Fever is the most common early sign, although
hypothermia may be present in patients with shock.
Confusion is present in 55% of patients, and in some,
coma or combativeness is manifest (8). Eighty per-
cent of patients have clinical signs of soft tissue
infection, such as localized swelling and erythema,
which in 70% of patients progressed to necrotizing
fasciitis or myositis and required surgical debride-
ment, fasciotomy or amputation (8). An ominous
sign is the progression of soft tissue swelling to the
formation of vesicles, then bullae, which appear
violaceous or bluish. In such patients, emergent
surgical exploration should be performed to estab-
lish the diagnosis and distinguish GAS infection
from other necrotizing soft tissue infections. Among
the 20% of patients without soft tissue findings,
clinical symptoms include endophthalmitis, myosi-
tis, perihepatitis, peritonitis, myocarditis, and over-
whelming sepsis. A diffuse, scarlatina-like erythema
occurs in only 10% of patients. Nearly 50% of pa-
tients may have normal blood pressure (systolic
pressure >110 mm Hg) on admission but develop
hypotension within the subsequent 4 hours (8).
Laboratory Evaluation of Patients 
On admission, renal involvement is indicated by
the presence of hemoglobinuria and by serum creat-
inine values that are, on average, >2.5 times normal.
Renal impairment precedes hypotension in 40% to
50% of patients (8). Hypoalbuminemia is associated
with hypocalcemia on admission and throughout the
hospital course. The serum creatinine kinase level
is useful in detecting deeper soft-tissue infections;
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correlation with necrotizing fasciitis or myositis.
Though the initial laboratory studies demonstrate
only mild leukocytosis, the mean percentage of imma-
ture neutrophils (including band forms, metamyelo-
cytes, and myelocytes) is striking, reaching 40% to
50%. Blood cultures are positive in 60% of cases (8).
Clinical Course
Shock is apparent at the time of admission or
within 4 to 8 hours in virtually all patients (Table
2). In only 10% of patients does systolic blood pres-
sure become normal 4 to 8 hours after administra-
tion of antibiotics, albumin, and electrolyte
solutions containing salts or dopamine; in all other
patients, shock persists. Similarly, renal dysfunc-
tion progresses or persists in all patients for 48 to 72
hours in spite of treatment, and many patients may
require dialysis (8). In patients who survive, serum
creatinine values return to normal within 4 to 6
weeks. Renal dysfunction precedes shock in many
patients and is apparent early in the course of shock
in all others. Acute respiratory distress syndrome
Table 1. Case definition of streptococcal toxic-shock syndrome (streptococcal TSS) and necrotizing fasciitis*
I. Streptococcal TSS
A. Isolation of group A Streptococcus
1. From a sterile site
2. From a nonsterile body site
B. Clinical signs of severity
1. Hypotension
2. Clinical and laboratory abnormalities (requires two or more of the following):
a) Renal impairment
b) Coagulopathy
c) Liver abnormalities
d) Acute respiratory distress syndrome
e) Extensive tissue necrosis, i.e., necrotizing fasciitis
f) Erythematous rash
Definite Case = A1 + B(1+2)
Probable Case = A2 + B(1+2)
II. Necrotizing fasciitis
A. Definite case
1. Necrosis of soft tissues with involvement of the fascia
PLUS
2. Serious systemic disease, including one or more of the following:
a) Death
b) Shock (systolic blood pressure <90 mm of Hg).
c) Disseminated intravascular coagulopathy
d) Failure of organ systems
a. respiratory failure
b. liver failure
c. renal failure
3. Isolation of group A Streptococcus from a normally sterile body site
B. Suspected case
1. 1  1 + 2 and serologic confirmation of group A streptococcal infection by a 4-fold rise against:
a) streptolysin O
b) DNase B
2. 1 + 2 and histologic confirmation:
Gram-positive cocci in a necrotic soft tissue infection
*Streptococcal toxic-shock syndrome (streptococcal TSS) is defined as any group A streptococcal infection associated with the
early onset of shock and organ failure. Definitions describing criteria for shock, organ failure, definite cases, and probable
cases are included below.
Source: reference 61.
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after the onset of hypotension (8). Supplemental
oxygen, intubation, and mechanical ventilation are
necessary in 90% of the patients in whom this syn-
drome develops. Mortality rates vary from 30% to
70% (1,8,24-26). Morbidity is also high; 13 of 20
patients in one series underwent major surgical
procedures, which included fasciotomy, surgical de-
bridement, exploratory laparotomy, intraocular as-
piration, amputation, or hysterectomy (8).
Clinical Isolates 
M types 1, 3, 12, and 28 have been the most
common isolates from patients with shock and mul-
tiorgan failure (8,29). Recently, 80% of strains in
Sweden from all types of GAS infection have been M
type 1 (S. Holm, pers. comm.). Pyrogenic exotoxin A
and/or B was found in most cases of severe infection.
In the United States, pyrogenic exotoxin A is most
frequently associated with these infections (8,23,29-
33), while in Sweden and the United Kingdom, exo-
toxin B has been most common (12,25). Recently,
streptococcal superantigen (SSA), a novel pyrogenic
exotoxin, was isolated from an M 3 strain, albeit in
small concentrations (34). In addition, mitogenic
factor (MF) has been demonstrated in many differ-
ent M types of GAS (35,36).
Necrotizing Fasciitis
Necrotizing fasciitis, a deep-seated infection of
the subcutaneous tissue that progressively destroys
fascia and fat but may spare the skin and muscle,
can be caused by GAS, Clostridium perfringens, or
C. septicum.  Necrotizing fasciitis caused by mixed
organisms such as aerobic gram-negative bacteria,
anaerobes, and microaerophilic streptococci may de-
velop in diabetic patients or patients with open
wounds contaminated with bowel contents. Though
Meleney called infections caused by hemolytic strep-
tococci “streptococcal gangrene” (37), the process
has been renamed necrotizing fasciitis. His patients’
infections began at the site of trivial or inapparent
trauma. Within 24 hours of the initial lesion—which
frequently was only mild erythema—swelling, heat,
erythema, and tenderness rapidly developed. Dur-
ing the next 24 to 48 hours, the erythema changed
from red to purple and then to blue, and blisters and
bullae, which contained clear yellow fluid, appeared.
On days 4 and 5, the purple areas became gangre-
nous. From day 7 to day 10, the line of demarcation
became sharply defined, and the dead skin began to
separate at the margins or breaks in the center,
revealing an extensive necrosis of the subcutaneous
tissue. In more severe cases, the process advanced
rapidly until several large areas of skin became
gangrenous, and the intoxication rendered the pa-
tient dull, unresponsive, mentally cloudy, or even
delirious. Meleney was the first to advocate aggres-
sive “bear scratch” fasciotomy and debridement.
With this treatment, together with irrigation with
Dakains solution, the mortality rate dropped to 20%
(37).
These older reports of necrotizing fasciitis (6)
differ from reports of current necrotizing fasciitis
cases associated with streptococcal TSS (8). First,
recent cases have mainly occurred in young healthy
persons who had no underlying disease but sus-
tained minor trauma to an extremity. Earlier series
describe older patients with multiple medical prob-
lems (6). Meleney’s cases (reported from China) were
probably among young healthy persons who sus-
tained minor trauma, though the major difference
between them and present cases is the low mortality
rate (20% vs 20% to 60% in streptococcal TSS ) (6,37)
before antibiotics were available (37). Analysis of
Meleney’s reports also suggests that most of his
patients did not have shock or organ failure, nor did
they require amputation. In contrast, present cases
of necrotizing fasciitis caused by GAS are invariably
associated with severe manifestations of systemic
illness and high morbidity despite the absence of
underlying disease and the use of antibiotics, dialy-
sis, ventilators, intravenous fluids, and improved
surgical techniques. In summary, the high mortality
rate among current cases of streptococcal necrotiz-
ing fasciitis could be due to the emergence of more
virulent streptococci (8).
Streptococcal Myositis
Streptococcal myositis is an extremely uncom-
mon GAS infection. Adams et al. (38) documented
only 21 reported cases from 1900 to 1985, and Svane
(39) found only four cases in more 20,000 autopsies.
Severe pain may be the only early symptom, and
swelling and erythema may be the only early physi-
cal findings, though muscle compartment syn-
dromes may develop rapidly (8-10,38-41).
Distinguishing streptococcal myositis from sponta-
neous gas gangrene caused by C. perfringens or C.
septicum (42) may be difficult, though crepitus or
demonstration of gas in the tissue favors clostridial
infection (40). Patients with streptococcal TSS may
Table 2. Complications of group A streptococcal soft-tissue
infection
Complication
Percentage
of Patients
Shock 95
Acute respiratory distress syndrome 55
Renal impairment 80
 Irreversible 10
 Reversible 70
Bacteremia 60
Death 30
Source: reference 1.
Synopses
Emerging Infectious Diseases 72 Vol. 1, No. 3 — July-September 1995have both necrotizing fasciitis and myositis (8,38).
In published series, the case-fatality rate for ne-
crotizing fasciitis is 20% to 50%, whereas GAS
myositis has a fatality rate of 80% to 100% (6).
Aggressive surgical debridement is extremely im-
portant for establishing a diagnosis and removing
devitalized tissue.
Bacteremia
Streptococcal bacteremia has occurred most com-
monly in the very young and in the elderly (5).
Among children, predisposing factors (other than
scarlet fever) include burns, varicella, malignant
neoplasm, immunosuppression, and age less than 2
years (5). In patients with scarlet fever, the pharynx
is the most common source of GAS. Frequently such
patients have complications, such as extension of
infection into the sinuses, peritonsillar tissue, or
mastoids (septic scarlet fever or scarlet fever angi-
nose); yet documented bacteremia occurs in only
0.3% of febrile patients (43). Among the children
with varicella studied by Bullowa and Wischik (43),
GAS bacteremia occurred in only approximately
0.5% of patients.
In elderly patients the source of GAS infection is
invariably the skin and is associated with cellulitis
or erysipelas (5). GAS sepsis in the elderly (mean
age, 50 to 60 years) has also been associated with
diabetes, peripheral vascular disease, malignancy,
and corticosteroid use. Not surprising, mortality
rates of 35% to 80% have been described in this
patient population. In the past, GAS bacteremia was
rare among persons 14 to 40 years of age; puerperal
sepsis accounted for most bacteremia in this age
group. Recently, intravenous drug abuse has
emerged as a leading cause of GAS bacteremia in
this age group (5). Martin and Hoiby have compre-
hensively demonstrated that the prevalence of GAS
bacteremia in Norway in the late 1980s increased in
all age groups, but the greatest increase (600% to
800%) was in adolescents and young adults (10).
Thus, the demographics of invasive streptococcal
infections have changed dramatically in the past 4
to 6 years.
Current Hypotheses Regarding Mechanisms of
Shock and Tissue Destruction Caused by Virulent
Group A Streptococci
Pyrogenic exotoxins cause fever in humans and
animals and also help induce shock by lowering the
threshold to exogenous endotoxin (5). Streptococcal
pyrogenic exotoxins A and B induce human mononu-
clear cells to synthesize not only tumor necrosis
factor-a (TNFa) (44) but also interleukin-1b (IL-1b)
(45) and interleukin-6 (IL-6) (45), suggesting that
TNF could mediate the fever, shock, and tissue
injury observed in patients with streptococcal TSS
(8). Pyrogenic exotoxin C has been associated with
mild cases of scarlet fever in the United States
(author’s observations) and in England (46). The
roles of two newly described pyrogenic exotoxins,
SSA and MF (see section on “Clinical Isolates”), in
streptococcal TSS have not been elucidated.
M protein contributes to invasiveness through its
ability to impede phagocytosis of streptococci by
human polymorphonuclear leukocytes (47). Con-
versely, type-specific antibody against the M protein
enhances phagocytosis (47). After infection with a
particular M type, specific antibody confers resis-
tance to challenge to viable GAS of that M type (47).
While M types 1 and 3 strains have accounted for
most strains isolated from cases of streptococcal
TSS, many other M types, including some nontyp-
able strains, have also been isolated from such cases.
M types 1 and 3 are also commonly isolated from
asymptomatic carriers, patients with pharyngitis,
and patients with mild scarlet fever (7,29).
Could streptococcal TSS be related to the ability
of pyrogenic exotoxin or M proteins type 1 or 3 to act
as “super antigens” (48)? Data suggest that this
exotoxin and a number of staphylococcal toxins
(toxic shock syndrome toxin-1 [TSST-1] and staphy-
lococcal enterotoxins A, B, and C) can stimulate
T-cell responses through their ability to bind to both
the Class II major histocompatibility ability com-
plex of antigen-presenting cells and the Vb region of
the T-cell receptor (48). The net effect would be to
induce T-cell stimulation with production of cyto-
kines capable of mediating shock and tissue injury.
Recently, Hackett and Stevens demonstrated that
pyrogenic exotoxin A induced both TNFa and TNFb
from mixed cultures of monocytes and lymphocytes
(49), supporting the role of lymphokines (TNFb) in
shock associated with strains producing that exo-
toxin. Kotb et al. (50) have shown that a digest of M
protein type 6 can also stimulate T-cell responses by
this mechanism; however, the role of specific super-
antigens in this or any other infectious disease has
not been proven. Proof would require demonstration
of massive expansion of T-cell subsets bearing a Vb
repertoire specific for the putative superantigen.
However, quantitation of such T-cell subsets in pa-
tients with acute streptococcal TSS demonstrated
deletion rather than expansion, suggesting that per-
haps the life span of the expanded subset was short-
ened by a process of apoptosis (51). In addition, the
subsets deleted were not specific for streptococcal
pyrogenic exotoxins A, B, C, or mitogenic factor,
suggesting that an as yet undefined superantigen
may play a role (51).
Cytokine production by less exotic mechanisms
likely contributes as well to the genesis of shock and
organ failure. Peptidoglycan, lipoteichoic acid (52),
and killed organisms (53,54) are capable of inducing
TNFa production by mononuclear cells in vitro
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are also potent inducers of TNFa and IL-1b. Pyro-
genic exotoxin B, a proteinase precursor, has the
ability to cleave pre-IL-1b to release preformed IL-
1b (56). Finally, SLO and exotoxin A together have
additive effects in the induction of IL-1b by human
mononuclear cells (49). Whatever the mechanisms,
induction of cytokines in vivo is likely the cause of
shock, and these two exotoxins, cell wall compo-
nents, and the like, are potent inducers of TNF and
IL-1.
The mere presence of virulence factors, such as
M protein or pyrogenic exotoxins, may be less impor-
tant in streptococcal TSS than the dynamics of their
production in vivo. Recently, Cleary et al. proposed
a regulon in GAS that controls the expression of a
group of virulence genes coding for known virulence
factors such as M protein and C5 peptidase (57).
When DNA fingerprinting was used, differences
were shown between M1 strains isolated from
patients with invasive disease and strains from pa-
tients with noninvasive GAS infections (58). Finally,
genetic information coding for exotoxins A or C may
be introduced to strains of GAS by certain bacterio-
phage; after lysogenic conversion, synthesis of exo-
toxin A would occur during growth of the
streptococcus (31,59,60). Multilocus enzyme electro-
phoresis demonstrates two patterns that correspond
to the M1 and M3 type organisms that produce
pyrogenic exotoxin A, a finding that supports
epidemiologic studies implicating these strains in
invasive GAS infections (33).
The interaction between these microbial viru-
lence factors and an immune or nonimmune host
determines the epidemiology, clinical syndrome, and
outcome. Since horizontal transmission of GAS in
general is well documented, the only explanation for
the absence of a high attack rate of invasive infection
is significant herd immunity against one or more of
the virulence factors responsible for streptococcal
TSS. This hypothetical model explains why epidem-
ics have not materialized and why a particular
strain of GAS can cause different clinical manifes-
tations in the same community (8,61) (Figure 1).
Treatment
Antibiotic Therapy – Cures and Failures with
Penicillin
S. pyogenes continues to be exquisitely suscepti-
ble to ß-lactam antibiotics, and numerous studies
have demonstrated the clinical efficacy of penicillin
preparations for streptococcal pharyngitis. Simi-
larly, penicillins and cephalosporins have proven
efficacy in treating erysipelas, impetigo, and celluli-
tis, all of which are most frequently caused by S.
pyogenes. In addition, Wannamaker et al. (6) dem-
onstrated that penicillin therapy prevents the devel-
opment of rheumatic fever following streptococcal
pharyngitis if therapy is begun within 8 to 10 days
of the onset of sore throat. Nonetheless, some clini-
cal failures of penicillin treatment of streptococcal
infection do occur. Penicillin treatment of S. pyo-
genes has failed to eradicate bacteria from the phar-
ynx of 5% to 20% of patients with documented
streptococcal pharyngitis (62-64). In addition, more
aggressive GAS infections (such as, necrotizing fas-
ciitis, empyema, burn wound sepsis, subcutaneous
gangrene, and myositis) respond less well to penicil-
lin and continue to be associated with high mortality
rates and extensive morbidity (6,8,9,12,15,38,65).
For example, in a recent report, 25 cases of strepto-
coccal myositis had an overall mortality rate of 85%
in spite of penicillin therapy (38). Finally, several
studies in experimental infection suggest that peni-
cillin fails when large numbers of organisms are
present (66,67).
The Efficacy of Penicillin, Compared to Clindamycin,
In Fulminant Experimental S. pyogenes Infection
In a mouse model of myositis caused by S. pyo-
genes, penicillin was ineffective when treatment was
delayed  ³2 hours after initiation of infection (67).
Survival of erythromycin-treated mice was greater
than that of both penicillin-treated mice and un-
treated controls, but only if treatment was begun
within 2 hours. Mice receiving clindamycin, how-
ever, had survival rates of 100%, 100%, 80%, and
70%, even if treatment was delayed 0, 2, 6, and 16.5
hours, respectively (67,68).
Eagle suggested that penicillin failed in this type
of infection because of the “physiologic state of the
Figure 1. Pathogenesis of scarlet fever, bacteremia, and
toxic shock syndrome. M-1+ SPEA+ = a GAS strain that
contains M protein type 1 and streptococcal pyrogenic
exotoxin A (SPEA); +anti-M-1 = the presence of
antibody to M protein type 1; -anti-M-1 = the absence
of antibody to M protein type 1’; anti-SPEA+ = antibody
to SPEA; and DIC - disseminated intravascular
coagulation.
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attributed to both in vitro and in vivo inoculum
effects (69,70).
Inoculum Size and the “Physiologic State of the
Organism”: Differential Expression of Penicillin-
Binding Proteins
Penicillin and other ß-lactam antibiotics are most
efficacious against rapidly growing bacteria. We hy-
pothesized that large inocula reach the stationary
phase of growth sooner than smaller inocula both in
vitro and in vivo. That high concentrations of S.
pyogenes accumulate in deep-seated infection is sup-
ported by data from Eagle et al. (66). We compared
the penicillin-binding protein patterns from mem-
brane proteins of group A streptococci isolated from
different stages of growth, i.e., mid-log phase and
stationary phase. Binding of radiolabeled penicillin
by all penicillin-binding proteins was decreased in
stationary cells; however, PBPs 1 and 4 were unde-
tectable at 36 hours (69). Thus, the loss of certain
penicillin-binding proteins during stationary-phase
growth in vitro may be responsible for the inoculum
effect observed in vivo and may account for the
failure of penicillin in treatment of both experimen-
tal and human cases of severe streptococcal infec-
tion.
The Greater Efficacy of Clindamycin in Experimental
S. pyogenes Infections: Mechanisms of Action
The greater efficacy of clindamycin is likely mul-
tifactorial: First, its efficacy is not affected by inocu-
lum size or stage of growth (69,71); secondly,
clindamycin is a potent suppressor of bacterial toxin
synthesis (72,73); third, it facilitates phagocytosis of
S. pyogenes by inhibiting M-protein synthesis (73);
fourth, it suppresses synthesis of penicillin-binding
proteins, which, in addition to being targets for
penicillin, are also enzymes involved in cell wall
synthesis and degradation (71); fifth, clindamycin
has a longer postantibiotic effect than ß-lactams
such as penicillin; and lastly, clindamycin causes
suppression of LPS-induced monocyte synthesis of
TNF (74). Thus, clindamycin’s efficacy may also be
related to its ability to modulate the immune re-
sponse.
Other Treatment Measures
Though antibiotic selection is critically impor-
tant, other measures, such as prompt and aggres-
sive exploration and debridement of suspected
deep-seated S. pyogenes infection, are mandatory.
Frequently, the patient has fever and excruciating
pain. Later, systemic toxicity develops, and definite
evidence of necrotizing fasciitis and myositis ap-
pears. Surgical debridement may be too late at this
point. Prompt surgical exploration through a small
incision with visualization of muscle and fascia, and
timely Gram stain of surgically obtained material
may provide an early and definitive etiologic diag-
nosis. Surgical colleagues should be involved early
in such cases, since later in the course surgical
intervention may be impossible because of toxicity
or because infection has extended to vital areas
impossible to debride (i.e., the head and neck, tho-
rax, or abdomen).
Anecdotal reports suggest that hyperbaric oxy-
gen has been used in a handful of patients, though
no controlled studies are under way, nor is it clear
that this treatment is useful.
Because of intractable hypotension and diffuse
capillary leak, massive amounts of intravenous flu-
ids (10 to 20 liters/day) are often necessary. Pressors
such as dopamine are used frequently, though no
controlled trials have been performed in streptococ-
cal TSS. In patients with intractable hypotension,
vasoconstrictors such as epinephrine have been
used, but symmetrical gangrene of digits seems to
result frequently (author’s unpublished observa-
tions), often with loss of limb. In these cases it is
difficult to determine if symmetrical gangrene is due
to pressors, infection, or both.
Neutralization of circulating toxins would be de-
sirable; however, appropriate antibodies are not
commercially available in the United States or
Europe. Two reports describe the successful use of
intravenous gamma globulin in treating streptococ-
cal TSS in two patients (75,76).
In summary, if a wild “flesh-eating strain” has
recently emerged, a major epidemic with a high
attack rate would normally be expected. Clearly,
epidemics of streptococcal infections, including im-
petigo, pharyngitis, scarlet fever, and rheumatic fe-
ver have occurred in the past. However, in the last
decade, subsequent to early reports of streptococcal
TSS, we have observed that the incidence has re-
mained relatively low. I hypothesize that large out-
breaks have not occurred because 1) most of the
population probably has immunity to one or more
streptococcal virulence factors (6,25); 2) predispos-
ing conditions (e.g., varicella, and use of NSAIDs)
are required in a given patient; and 3) only a small
percentage of the population may have an inherent
predisposition to severe streptococcal infection be-
cause of constitutional factors such as HLA Class II
antigen type (77,78), B-cell (79), or specific Vb re-
gions on lymphocytes. This last hypothesis is further
supported by the observation that secondary cases
of streptococcal TSS, though reported (80), have
been rare.
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